InMed Pharmaceuticals adds John Bathery to board of directors

InMed Pharmaceuticals Inc. (NASDAQ: INM) appointed John Bathery to its board of directors, effective immediately, according to a company statement.

Bathery brings over 30 years of pharmaceutical industry experience, including more than 15 years in corporate development and strategic partnerships. He currently serves as Head of Global Business Development Operations & Externalization at Takeda Pharmaceuticals, where he oversees pipeline and commercial divestitures, global alliance management, and integration of corporate transactions.

During his career, Bathery has led transactions with financial terms exceeding $60 billion across mergers and acquisitions, licensing, divestments, and collaborations, according to the company.

"I am pleased to join InMed's Board at this pivotal stage in the Company's growth," Bathery stated. "The consistent positive results seen with INM-901 across multiple parameters are particularly encouraging and highlight the strength of InMed's research."

The Vancouver-based pharmaceutical company is developing small molecule drug candidates for diseases with unmet medical needs, including its INM-901 program for Alzheimer's disease and INM-089 program for age-related macular degeneration.

InMed also announced that Bryan Baldasare will not stand for re-election at the company's December 18, 2025 Annual General Meeting due to increasing professional obligations.

Andrew Hull, chairman of InMed's board, said Bathery's deal-making expertise and ability to structure partnerships at the preclinical stage will support the company's development programs and strategic collaborations.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• reAlpha completes $8.5M InstaMortgage acquisition
• Kairos Pharma announces 1-for-7 reverse stock split